Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus trastuzumab and pertuzumab in molecular HER2-enriched early breast cancer
2018-003996-37Phase 2Completed
- Sponsor
- Westdeutsche Studiengruppe
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, pertuzumab and trastuzumab in breast cancer, sponsored by Westdeutsche Studiengruppe. Primary endpoint: Pathologic complete response. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-003996-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003996-37.